Altay Therapeutics
Biopharmaceutical company developing small molecule transcription factor inhibitors for serious, underserved diseases, with a therapeutic area-agnostic drug discovery platform targeting allosteric sites on transcription factors.
About Altay Therapeutics
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue.
With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion.
We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue.
With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
Products
First oral small molecule inhibitor of DUX4 for facioscapulohumeral muscular dystrophy (FSHD).
Small molecule inhibitor that binds directly to the activated form of STAT3, demonstrating nanomolar potency, broad therapeutic relevance, and minimal off-target effects.
Early candidates against an undisclosed transcription factor with relevance in sarcomas and prostate cancer.
Security and compliance
No security details published yet
Altay Therapeutics hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim Altay Therapeutics